FBLG - FibroBiologics, Inc.
1.53
0.010 0.654%
Share volume: 704,339
Last Updated: 04-17-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.17%
PREVIOUS CLOSE
CHG
CHG%
$1.52
0.01
0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2024 | 08-07-2024 | 11-12-2024 | 05-14-2025 | 07-31-2025 | 10-31-2025 | 02-24-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | nan% | |||
| Operating expenses | 3.450 M | 3.224 M | 3.352 M | 4.531 M | 4.490 M | 5.038 M | 2.590 M | |
| Selling general and admin | 2.490 M | 2.249 M | 2.139 M | 2.751 M | 2.449 M | 2.249 M | 1.793 M | |
| Research and development | 960.000 K | 975.000 K | 1.213 M | 1.780 M | 2.041 M | 2.789 M | 797.000 K | |
| Total expenses | 3.450 M | 3.224 M | 3.352 M | 4.531 M | 4.490 M | 5.038 M | 2.590 M | |
| -6.55% | 3.97% | 35.17% | -0.90% | 12.20% | -48.59% | |||
| Operating income | -3.450 M | -3.224 M | -3.352 M | -4.531 M | -4.490 M | -5.038 M | -2.590 M | |
| Ebit | -6.554 M | 803.000 K | -574.000 K | -5.065 M | -4.083 M | -5.851 M | -3.071 M | |
| Pretax income | -8.460 M | 868.000 K | -500.000 K | -4.966 M | -4.033 M | -5.778 M | -3.250 M | |
| -110.26% | -157.60% | 893.20% | -18.79% | 43.27% | -43.75% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -8.460 M | 898.000 K | -500.000 K | -4.966 M | -4.658 M | -5.778 M | -3.244 M | |
| 110.61% | -155.68% | -893.20% | 6.20% | -24.04% | 43.86% |